Novomedix, Inc.

San Diego, CA 92121
http://novomedix.com/

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $3.86MM
First Award Date 04/01/07
Most Recent Award Date 04/01/16

Key Personnel

Last Name Name Awards Contact
Swindlehurst Cathy A Swindlehurst 9
Payne Kimberly J Payne 2
LEFER DAVID JOSEPH LEFER 1

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 04/01/16 - 03/31/17

? DESCRIPTION (provided by applicant): The overall goal for this project is the development of safer, more effective drugs for the treatment of heart failure. Heart disease is the number one cause of death worldwide and the #1 killer of women - more than all forms of cancer combined. One in 9 deaths in the US are heart failure related. The pr...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/01/14 - 08/31/15

DESCRIPTION (provided by applicant): The goal of this program is to complete the appropriate preclinical studies to support an IND for a first-in- class small molecule therapeutic for triple negative (estrogen receptor, progesterone receptor, and HER2 negative) breast cancer with an emphasis on reducing recurrence and increasing survival rates. ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): The goal of this program is to complete the appropriate preclinical studies to support an IND for a first-in- class small molecule therapeutic for triple negative (estrogen receptor, progesterone receptor, and HER2 negative) breast cancer with an emphasis on reducing recurrence and increasing survival rates. ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): The goal of this program is to develop and ultimately commercialize small molecule drugs for the treatment of high risk pediatric B-cell acute lymphoblastic leukemia (B-ALL), with an initial focus on drug resistant B-ALL. B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignancy and ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/18/12 - 08/31/13

DESCRIPTION (provided by applicant): The goal of this program is to complete the appropriate preclinical studies to support an IND for a first-in- class small molecule therapeutic for triple negative (estrogen receptor, progesterone receptor, and HER2 negative) breast cancer with an emphasis on reducing recurrence and increasing survival rates. ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 09/17/12 - 08/31/13

DESCRIPTION (provided by applicant): The goal of this program is to develop and ultimately commercialize small molecule drugs for the treatment of high risk pediatric B-cell acute lymphoblastic leukemia (B-ALL), with an initial focus on drug resistant B-ALL. B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignancy and ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 08/01/10 - 07/31/11

DESCRIPTION (provided by applicant): The goal of this program is to develop and ultimately commercialize small molecule drugs that inhibit cap- dependent translation initiation for the treatment of triple negative (estrogen receptor, progesterone receptor, and HER2 negative) breast tumors with an emphasis on reducing recurrence and increasing su...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-DK-05-16
Budget: 04/01/08 - 03/31/10

DESCRIPTION (provided by applicant): The goal of this program is to develop and ultimately commercialize small molecule drugs that induce (-cell replication and/or differentiation for the treatment and potential cure of type 1 diabetes (T1D). Molecules that induce (-cell regeneration will be identified using high-throughput, high-content scree...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-DK-05-16
Budget: 04/01/07 - 03/31/08

DESCRIPTION (provided by applicant): The goal of this program is to develop and ultimately commercialize small molecule drugs that induce (-cell replication and/or differentiation for the treatment and potential cure of type 1 diabetes (T1D). Molecules that induce (-cell regeneration will be identified using high-throughput, high-content scree...